ID   PLK3_HUMAN              Reviewed;         646 AA.
AC   Q9H4B4; Q15767; Q5JR99; Q96CV1;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   16-AUG-2004, sequence version 2.
DT   15-MAR-2017, entry version 160.
DE   RecName: Full=Serine/threonine-protein kinase PLK3;
DE            EC=2.7.11.21;
DE   AltName: Full=Cytokine-inducible serine/threonine-protein kinase;
DE   AltName: Full=FGF-inducible kinase;
DE   AltName: Full=Polo-like kinase 3;
DE            Short=PLK-3;
DE   AltName: Full=Proliferation-related kinase;
GN   Name=PLK3; Synonyms=CNK, FNK, PRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryo;
RX   PubMed=11039900; DOI=10.1038/sj.onc.1203845;
RA   Holtrich U., Wolf G., Yuan J., Bereiter-Hahn J., Karn T., Weiler M.,
RA   Kauselmann G., Rehli M., Andreesen R., Kaufmann M., Kuhl D.,
RA   Strebhardt K.;
RT   "Adhesion induced expression of the serine/threonine kinase Fnk in
RT   human macrophages.";
RL   Oncogene 19:4832-4839(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-61; PHE-68;
RP   PHE-283; CYS-483; LEU-498 AND PRO-618.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-491.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-646.
RC   TISSUE=Placenta;
RX   PubMed=8702627; DOI=10.1074/jbc.271.32.19402;
RA   Li B., Ouyang B., Pan H., Reissmann P.T., Slamon D.J., Arceci R.,
RA   Lu L., Dai W.;
RT   "Prk, a cytokine-inducible human protein serine/threonine kinase whose
RT   expression appears to be down-regulated in lung carcinomas.";
RL   J. Biol. Chem. 271:19402-19408(1996).
RN   [7]
RP   INDUCTION.
RX   PubMed=11746980; DOI=10.1002/gcc.1204;
RA   Wiest J., Clark A.M., Dai W.;
RT   "Intron/exon organization and polymorphisms of the PLK3/PRK gene in
RT   human lung carcinoma cell lines.";
RL   Genes Chromosomes Cancer 32:384-389(2001).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF TP53 AND CHEK2, AND PHOSPHORYLATION.
RX   PubMed=12242661; DOI=10.1038/sj.onc.1205850;
RA   Bahassi el M., Conn C.W., Myer D.L., Hennigan R.F., McGowan C.H.,
RA   Sanchez Y., Stambrook P.J.;
RT   "Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein
RT   involved in stress response pathways.";
RL   Oncogene 21:6633-6640(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=9353331; DOI=10.1074/jbc.272.45.28646;
RA   Ouyang B., Pan H., Lu L., Li J., Stambrook P., Li B., Dai W.;
RT   "Human Prk is a conserved protein serine/threonine kinase involved in
RT   regulating M phase functions.";
RL   J. Biol. Chem. 272:28646-28651(1997).
RN   [10]
RP   FUNCTION.
RX   PubMed=10557092; DOI=10.1038/sj.onc.1202983;
RA   Ouyang B., Li W., Pan H., Meadows J., Hoffmann I., Dai W.;
RT   "The physical association and phosphorylation of Cdc25C protein
RT   phosphatase by Prk.";
RL   Oncogene 18:6029-6036(1999).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF ASP-203.
RX   PubMed=11156373;
RA   Conn C.W., Hennigan R.F., Dai W., Sanchez Y., Stambrook P.J.;
RT   "Incomplete cytokinesis and induction of apoptosis by overexpression
RT   of the mammalian polo-like kinase, Plk3.";
RL   Cancer Res. 60:6826-6831(2000).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF LYS-91.
RX   PubMed=11447225; DOI=10.1074/jbc.M104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20
RT   is mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF TP53.
RX   PubMed=11551930; DOI=10.1074/jbc.M106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C.,
RA   Stambrook P., Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis
RT   at least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [14]
RP   FUNCTION.
RX   PubMed=11971976; DOI=10.1128/MCB.22.10.3450-3459.2002;
RA   Wang Q., Xie S., Chen J., Fukasawa K., Naik U., Traganos F.,
RA   Darzynkiewicz Z., Jhanwar-Uniyal M., Dai W.;
RT   "Cell cycle arrest and apoptosis induced by human Polo-like kinase 3
RT   is mediated through perturbation of microtubule integrity.";
RL   Mol. Cell. Biol. 22:3450-3459(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH GOLGB1, AND
RP   MUTAGENESIS OF LYS-91.
RX   PubMed=14980500; DOI=10.1016/j.yexcr.2003.10.022;
RA   Ruan Q., Wang Q., Xie S., Fang Y., Darzynkiewicz Z., Guan K.,
RA   Jhanwar-Uniyal M., Dai W.;
RT   "Polo-like kinase 3 is Golgi localized and involved in regulating
RT   Golgi fragmentation during the cell cycle.";
RL   Exp. Cell Res. 294:51-59(2004).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25C.
RX   PubMed=14968113; DOI=10.1038/sj.onc.1207425;
RA   Bahassi el M., Hennigan R.F., Myer D.L., Stambrook P.J.;
RT   "Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear
RT   translocation.";
RL   Oncogene 23:2658-2663(2004).
RN   [17]
RP   FUNCTION.
RX   PubMed=15021912; DOI=10.1038/sj.onc.1207479;
RA   Xie S., Wang Q., Ruan Q., Liu T., Jhanwar-Uniyal M., Guan K., Dai W.;
RT   "MEK1-induced Golgi dynamics during cell cycle progression is partly
RT   mediated by Polo-like kinase-3.";
RL   Oncogene 23:3822-3829(2004).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-219 AND
RP   467-TRP-VAL-468.
RX   PubMed=16478733; DOI=10.1074/jbc.M513156200;
RA   Jiang N., Wang X., Jhanwar-Uniyal M., Darzynkiewicz Z., Dai W.;
RT   "Polo box domain of Plk3 functions as a centrosome localization
RT   signal, overexpression of which causes mitotic arrest, cytokinesis
RT   defects, and apoptosis.";
RL   J. Biol. Chem. 281:10577-10582(2006).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF TP53 AND CHEK2.
RX   PubMed=16481012; DOI=10.1016/j.mrfmmm.2005.12.002;
RA   Bahassi el M., Myer D.L., McKenney R.J., Hennigan R.F.,
RA   Stambrook P.J.;
RT   "Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates
RT   its full activation by ATM and a downstream checkpoint in response to
RT   DNA damage.";
RL   Mutat. Res. 596:166-176(2006).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF JUN, AND MUTAGENESIS OF LYS-91.
RX   PubMed=17804415; DOI=10.1074/jbc.M702791200;
RA   Wang L., Dai W., Lu L.;
RT   "Stress-induced c-Jun activation mediated by Polo-like kinase 3 in
RT   corneal epithelial cells.";
RL   J. Biol. Chem. 282:32121-32127(2007).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=17264206; DOI=10.1073/pnas.0610856104;
RA   Zimmerman W.C., Erikson R.L.;
RT   "Polo-like kinase 3 is required for entry into S phase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1847-1852(2007).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF TOP2A.
RX   PubMed=18062778; DOI=10.1042/BJ20071394;
RA   Iida M., Matsuda M., Komatani H.;
RT   "Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that
RT   is not recognized by Plk1.";
RL   Biochem. J. 411:27-32(2008).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF JUN, AND SUBCELLULAR LOCATION.
RX   PubMed=18650425; DOI=10.1074/jbc.M801326200;
RA   Wang L., Gao J., Dai W., Lu L.;
RT   "Activation of Polo-like kinase 3 by hypoxic stresses.";
RL   J. Biol. Chem. 283:25928-25935(2008).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF TP73, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF LYS-91.
RX   PubMed=19490146; DOI=10.1111/j.1365-2443.2009.01309.x;
RA   Sang M., Ando K., Okoshi R., Koida N., Li Y., Zhu Y., Shimozato O.,
RA   Geng C., Shan B., Nakagawara A., Ozaki T.;
RT   "Plk3 inhibits pro-apoptotic activity of p73 through physical
RT   interaction and phosphorylation.";
RL   Genes Cells 14:775-788(2009).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF VRK1, AND MUTAGENESIS OF LYS-91.
RX   PubMed=19103756; DOI=10.1128/MCB.01341-08;
RA   Lopez-Sanchez I., Sanz-Garcia M., Lazo P.A.;
RT   "Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a
RT   downstream target in a pathway that induces Golgi fragmentation.";
RL   Mol. Cell. Biol. 29:1189-1201(2009).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF HIF1A, AND MUTAGENESIS OF LYS-91.
RX   PubMed=20889502; DOI=10.1074/jbc.M110.160325;
RA   Xu D., Yao Y., Lu L., Costa M., Dai W.;
RT   "Plk3 functions as an essential component of the hypoxia regulatory
RT   pathway by direct phosphorylation of HIF-1alpha.";
RL   J. Biol. Chem. 285:38944-38950(2010).
RN   [27]
RP   FUNCTION IN PHOSPHORYLATION OF PTEN, AND MUTAGENESIS OF LYS-91.
RX   PubMed=20940307; DOI=10.1074/jbc.M110.166462;
RA   Xu D., Yao Y., Jiang X., Lu L., Dai W.;
RT   "Regulation of PTEN stability and activity by Plk3.";
RL   J. Biol. Chem. 285:39935-39942(2010).
RN   [28]
RP   FUNCTION, INTERACTION WITH CIB1, AND SUBCELLULAR LOCATION.
RX   PubMed=20951827; DOI=10.1016/j.biocel.2010.10.003;
RA   Naik M.U., Naik U.P.;
RT   "Calcium- and integrin-binding protein 1 regulates microtubule
RT   organization and centrosome segregation through polo like kinase 3
RT   during cell cycle progression.";
RL   Int. J. Biochem. Cell Biol. 43:120-129(2011).
RN   [29]
RP   INTERACTION WITH CIB1.
RX   PubMed=20473878; DOI=10.1002/ijc.25388;
RA   Naik M.U., Pham N.T., Beebe K., Dai W., Naik U.P.;
RT   "Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1
RT   in breast cancer cells.";
RL   Int. J. Cancer 128:587-596(2011).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF ATF2, AND SUBCELLULAR LOCATION.
RX   PubMed=21098032; DOI=10.1074/jbc.M110.166009;
RA   Wang L., Payton R., Dai W., Lu L.;
RT   "Hyperosmotic stress-induced ATF-2 activation through Polo-like kinase
RT   3 in human corneal epithelial cells.";
RL   J. Biol. Chem. 286:1951-1958(2011).
RN   [31]
RP   FUNCTION IN PHOSPHORYLATION OF BCL2L1.
RX   PubMed=21840391; DOI=10.1016/j.cellsig.2011.07.017;
RA   Wang J., Beauchemin M., Bertrand R.;
RT   "Bcl-xL phosphorylation at Ser49 by polo kinase 3 during cell cycle
RT   progression and checkpoints.";
RL   Cell. Signal. 23:2030-2038(2011).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25A.
RX   PubMed=21376736; DOI=10.1016/j.mrfmmm.2011.02.006;
RA   Myer D.L., Robbins S.B., Yin M., Boivin G.P., Liu Y., Greis K.D.,
RA   Bahassi el M., Stambrook P.J.;
RT   "Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA
RT   damage but is not sufficient to produce tumors.";
RL   Mutat. Res. 714:1-10(2011).
RN   [33]
RP   FUNCTION, AND INTERACTION WITH CIB1.
RX   PubMed=21264284; DOI=10.1371/journal.pone.0014513;
RA   Kostyak J.C., Naik U.P.;
RT   "Calcium- and integrin-binding protein 1 regulates endomitosis and its
RT   interaction with Polo-like kinase 3 is enhanced in endomitotic Dami
RT   cells.";
RL   PLoS ONE 6:E14513-E14513(2011).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=20671765; DOI=10.1038/nrd3184;
RA   Strebhardt K.;
RT   "Multifaceted polo-like kinases: drug targets and antitargets for
RT   cancer therapy.";
RL   Nat. Rev. Drug Discov. 9:643-660(2010).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in cell cycle
CC       regulation, response to stress and Golgi disassembly. Polo-like
CC       kinases act by binding and phosphorylating proteins are that
CC       already phosphorylated on a specific motif recognized by the POLO
CC       box domains. Phosphorylates ATF2, BCL2L1, CDC25A, CDC25C, CHEK2,
CC       HIF1A, JUN, p53/TP53, p73/TP73, PTEN, TOP2A and VRK1. Involved in
CC       cell cycle regulation: required for entry into S phase and
CC       cytokinesis. Phosphorylates BCL2L1, leading to regulate the G2
CC       checkpoint and progression to cytokinesis during mitosis. Plays a
CC       key role in response to stress: rapidly activated upon stress
CC       stimulation, such as ionizing radiation, reactive oxygen species
CC       (ROS), hyperosmotic stress, UV irradiation and hypoxia. Involved
CC       in DNA damage response and G1/S transition checkpoint by
CC       phosphorylating CDC25A, p53/TP53 and p73/TP73. Phosphorylates
CC       p53/TP53 in response to reactive oxygen species (ROS), thereby
CC       promoting p53/TP53-mediated apoptosis. Phosphorylates CHEK2 in
CC       response to DNA damage, promoting the G2/M transition checkpoint.
CC       Phosphorylates the transcription factor p73/TP73 in response to
CC       DNA damage, leading to inhibit p73/TP73-mediated transcriptional
CC       activation and pro-apoptotic functions. Phosphorylates HIF1A and
CC       JUN is response to hypoxia. Phosphorylates ATF2 following
CC       hyperosmotic stress in corneal epithelium. Also involved in Golgi
CC       disassembly during the cell cycle: part of a MEK1/MAP2K1-dependent
CC       pathway that induces Golgi fragmentation during mitosis by
CC       mediating phosphorylation of VRK1. May participate in endomitotic
CC       cell cycle, a form of mitosis in which both karyokinesis and
CC       cytokinesis are interrupted and is a hallmark of megakaryocyte
CC       differentiation, via its interaction with CIB1.
CC       {ECO:0000269|PubMed:10557092, ECO:0000269|PubMed:11156373,
CC       ECO:0000269|PubMed:11447225, ECO:0000269|PubMed:11551930,
CC       ECO:0000269|PubMed:11971976, ECO:0000269|PubMed:12242661,
CC       ECO:0000269|PubMed:14968113, ECO:0000269|PubMed:14980500,
CC       ECO:0000269|PubMed:15021912, ECO:0000269|PubMed:16478733,
CC       ECO:0000269|PubMed:16481012, ECO:0000269|PubMed:17264206,
CC       ECO:0000269|PubMed:17804415, ECO:0000269|PubMed:18062778,
CC       ECO:0000269|PubMed:18650425, ECO:0000269|PubMed:19103756,
CC       ECO:0000269|PubMed:19490146, ECO:0000269|PubMed:20889502,
CC       ECO:0000269|PubMed:20940307, ECO:0000269|PubMed:20951827,
CC       ECO:0000269|PubMed:21098032, ECO:0000269|PubMed:21264284,
CC       ECO:0000269|PubMed:21376736, ECO:0000269|PubMed:21840391,
CC       ECO:0000269|PubMed:9353331}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts (via the POLO-box domain) with CIB1; leading to
CC       inhibit PLK3 kinase activity. Interacts with GOLGB1.
CC       {ECO:0000269|PubMed:14980500, ECO:0000269|PubMed:20473878,
CC       ECO:0000269|PubMed:20951827, ECO:0000269|PubMed:21264284}.
CC   -!- INTERACTION:
CC       P14859:POU2F1; NbExp=3; IntAct=EBI-751877, EBI-624770;
CC       P04156:PRNP; NbExp=4; IntAct=EBI-751877, EBI-977302;
CC       Q99986:VRK1; NbExp=12; IntAct=EBI-751877, EBI-1769146;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, nucleolus.
CC       Golgi apparatus. Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome. Note=Translocates to the nucleus upon
CC       cisplatin treatment. Localizes to the Golgi apparatus during
CC       interphase. According to a report, PLK3 localizes only in the
CC       nucleolus and not in the centrosome, or in any other location in
CC       the cytoplasm (PubMed:17264206). The discrepancies in results may
CC       be explained by the PLK3 antibody specificity, by cell line-
CC       specific expression or post-translational modifications.
CC       {ECO:0000269|PubMed:17264206}.
CC   -!- TISSUE SPECIFICITY: Transcripts are highly detected in placenta,
CC       lung, followed by skeletal muscle, heart, pancreas, ovaries and
CC       kidney and weakly detected in liver and brain. May have a short
CC       half-live. In cells of hematopoietic origin, strongly and
CC       exclusively detected in terminally differentiated macrophages.
CC       Transcript expression appears to be down-regulated in primary lung
CC       tumor.
CC   -!- DEVELOPMENTAL STAGE: Expression is cell cycle regulated with a
CC       peak in G1 phase. {ECO:0000269|PubMed:17264206}.
CC   -!- INDUCTION: Cytokine and cellular adhesion trigger induction. Down-
CC       regulated in a majority of lung carcinoma samples.
CC       {ECO:0000269|PubMed:11746980}.
CC   -!- DOMAIN: The POLO box domains act as phosphopeptide-binding module
CC       that recognize and bind serine-[phosphothreonine/phosphoserine]-
CC       (proline/X) motifs. PLK3 recognizes and binds docking proteins
CC       that are already phosphorylated on these motifs, and then
CC       phosphorylates them (By similarity). The POLO box domains mediates
CC       localization to the centrosome. {ECO:0000250}.
CC   -!- PTM: Phosphorylated in an ATM-dependent manner following DNA
CC       damage. Phosphorylated as cells enter mitosis and dephosphorylated
CC       as cells exit mitosis. {ECO:0000269|PubMed:12242661}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50637.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/plk3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ293866; CAC10659.1; -; mRNA.
DR   EMBL; AY764184; AAU88146.1; -; Genomic_DNA.
DR   EMBL; AL592166; CAI13006.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07021.1; -; Genomic_DNA.
DR   EMBL; BC013899; AAH13899.1; -; mRNA.
DR   EMBL; U56998; AAC50637.1; ALT_INIT; mRNA.
DR   CCDS; CCDS515.1; -.
DR   RefSeq; NP_004064.2; NM_004073.3.
DR   UniGene; Hs.632415; -.
DR   PDB; 4B6L; X-ray; 1.90 A; A=52-332.
DR   PDBsum; 4B6L; -.
DR   ProteinModelPortal; Q9H4B4; -.
DR   SMR; Q9H4B4; -.
DR   BioGrid; 107663; 13.
DR   IntAct; Q9H4B4; 8.
DR   MINT; MINT-110679; -.
DR   STRING; 9606.ENSP00000361275; -.
DR   BindingDB; Q9H4B4; -.
DR   ChEMBL; CHEMBL4897; -.
DR   GuidetoPHARMACOLOGY; 2170; -.
DR   iPTMnet; Q9H4B4; -.
DR   PhosphoSitePlus; Q9H4B4; -.
DR   BioMuta; PLK3; -.
DR   DMDM; 51338822; -.
DR   MaxQB; Q9H4B4; -.
DR   PaxDb; Q9H4B4; -.
DR   PeptideAtlas; Q9H4B4; -.
DR   PRIDE; Q9H4B4; -.
DR   DNASU; 1263; -.
DR   Ensembl; ENST00000372201; ENSP00000361275; ENSG00000173846.
DR   GeneID; 1263; -.
DR   KEGG; hsa:1263; -.
DR   UCSC; uc001cmn.4; human.
DR   CTD; 1263; -.
DR   DisGeNET; 1263; -.
DR   GeneCards; PLK3; -.
DR   H-InvDB; HIX0199969; -.
DR   HGNC; HGNC:2154; PLK3.
DR   HPA; HPA060318; -.
DR   MIM; 602913; gene.
DR   neXtProt; NX_Q9H4B4; -.
DR   OpenTargets; ENSG00000173846; -.
DR   PharmGKB; PA26664; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   eggNOG; ENOG410XQBP; LUCA.
DR   GeneTree; ENSGT00530000062954; -.
DR   HOGENOM; HOG000248546; -.
DR   HOVERGEN; HBG001843; -.
DR   InParanoid; Q9H4B4; -.
DR   KO; K08862; -.
DR   OMA; LCALRNC; -.
DR   OrthoDB; EOG091G0D89; -.
DR   PhylomeDB; Q9H4B4; -.
DR   TreeFam; TF101089; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; Q9H4B4; -.
DR   SIGNOR; Q9H4B4; -.
DR   ChiTaRS; PLK3; human.
DR   GeneWiki; PLK3; -.
DR   GenomeRNAi; 1263; -.
DR   PRO; PR:Q9H4B4; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000173846; -.
DR   CleanEx; HS_PLK3; -.
DR   Genevisible; Q9H4B4; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005795; C:Golgi stack; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0031122; P:cytoplasmic microtubule organization; IMP:UniProtKB.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; TAS:Reactome.
DR   GO; GO:0007113; P:endomitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0090166; P:Golgi disassembly; IDA:UniProtKB.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; TAS:UniProtKB.
DR   GO; GO:0044819; P:mitotic G1/S transition checkpoint; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:1904716; P:positive regulation of chaperone-mediated autophagy; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090316; P:positive regulation of intracellular protein transport; IMP:UniProtKB.
DR   GO; GO:2000777; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0051302; P:regulation of cell division; IDA:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0009314; P:response to radiation; IDA:UniProtKB.
DR   GO; GO:0000302; P:response to reactive oxygen species; IDA:UniProtKB.
DR   CDD; cd13118; POLO_box_1; 1.
DR   CDD; cd13117; POLO_box_2; 1.
DR   Gene3D; 3.30.1120.30; -; 2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033701; POLO_box_1.
DR   InterPro; IPR033695; POLO_box_2.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR020658; Ser/Thr_kinase_Plk3.
DR   PANTHER; PTHR24345:SF65; PTHR24345:SF65; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00659; POLO_box; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50078; POLO_BOX; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Cell cycle; Complete proteome;
KW   Cytoplasm; Cytoskeleton; DNA damage; Golgi apparatus; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    646       Serine/threonine-protein kinase PLK3.
FT                                /FTId=PRO_0000086564.
FT   DOMAIN       62    314       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      470    537       POLO box 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   DOMAIN      567    637       POLO box 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00154}.
FT   NP_BIND      68     76       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    185    185       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      91     91       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   VARIANT      61     61       T -> S (in dbSNP:rs17884581).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021091.
FT   VARIANT      68     68       L -> F (in dbSNP:rs17884316).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021092.
FT   VARIANT     283    283       L -> F (in dbSNP:rs17880471).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021093.
FT   VARIANT     483    483       R -> C (in dbSNP:rs17884653).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021094.
FT   VARIANT     491    491       D -> N (in dbSNP:rs17855444).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_062384.
FT   VARIANT     498    498       S -> L (in dbSNP:rs17880829).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021095.
FT   VARIANT     618    618       S -> P (in dbSNP:rs17881786).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_021096.
FT   MUTAGEN      91     91       K->R: Kinase defective mutant, abolishes
FT                                activity. {ECO:0000269|PubMed:11447225,
FT                                ECO:0000269|PubMed:14980500,
FT                                ECO:0000269|PubMed:17804415,
FT                                ECO:0000269|PubMed:19103756,
FT                                ECO:0000269|PubMed:19490146,
FT                                ECO:0000269|PubMed:20889502,
FT                                ECO:0000269|PubMed:20940307}.
FT   MUTAGEN     203    203       D->A: Kinase defective mutant, abolishes
FT                                activity. {ECO:0000269|PubMed:11156373}.
FT   MUTAGEN     219    219       T->E: Kinase-defective mutant.
FT                                {ECO:0000269|PubMed:16478733}.
FT   MUTAGEN     467    468       WV->FA: Abolishes localization to the
FT                                centrosome and ability to induce the G2/M
FT                                arrest. {ECO:0000269|PubMed:16478733}.
FT   CONFLICT     16     16       A -> T (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT     20     20       P -> T (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT     99     99       A -> V (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT    353    353       G -> V (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT    419    419       D -> H (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT    464    470       VSKWVDY -> FSEWVGF (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   CONFLICT    522    522       P -> R (in Ref. 1; CAC10659).
FT                                {ECO:0000305}.
FT   STRAND       62     69       {ECO:0000244|PDB:4B6L}.
FT   STRAND       75     81       {ECO:0000244|PDB:4B6L}.
FT   TURN         82     84       {ECO:0000244|PDB:4B6L}.
FT   STRAND       87     94       {ECO:0000244|PDB:4B6L}.
FT   HELIX        95     98       {ECO:0000244|PDB:4B6L}.
FT   HELIX       101    114       {ECO:0000244|PDB:4B6L}.
FT   STRAND      125    130       {ECO:0000244|PDB:4B6L}.
FT   STRAND      132    139       {ECO:0000244|PDB:4B6L}.
FT   HELIX       147    154       {ECO:0000244|PDB:4B6L}.
FT   HELIX       159    178       {ECO:0000244|PDB:4B6L}.
FT   HELIX       188    190       {ECO:0000244|PDB:4B6L}.
FT   STRAND      191    193       {ECO:0000244|PDB:4B6L}.
FT   STRAND      199    201       {ECO:0000244|PDB:4B6L}.
FT   TURN        213    215       {ECO:0000244|PDB:4B6L}.
FT   TURN        224    226       {ECO:0000244|PDB:4B6L}.
FT   HELIX       229    232       {ECO:0000244|PDB:4B6L}.
FT   HELIX       239    255       {ECO:0000244|PDB:4B6L}.
FT   HELIX       265    273       {ECO:0000244|PDB:4B6L}.
FT   HELIX       285    294       {ECO:0000244|PDB:4B6L}.
FT   HELIX       299    301       {ECO:0000244|PDB:4B6L}.
FT   HELIX       305    309       {ECO:0000244|PDB:4B6L}.
FT   HELIX       312    315       {ECO:0000244|PDB:4B6L}.
FT   HELIX       325    328       {ECO:0000244|PDB:4B6L}.
SQ   SEQUENCE   646 AA;  71629 MW;  324CA3E9DE482514 CRC64;
     MEPAAGFLSP RPFQRAAAAP APPAGPGPPP SALRGPELEM LAGLPTSDPG RLITDPRSGR
     TYLKGRLLGK GGFARCYEAT DTETGSAYAV KVIPQSRVAK PHQREKILNE IELHRDLQHR
     HIVRFSHHFE DADNIYIFLE LCSRKSLAHI WKARHTLLEP EVRYYLRQIL SGLKYLHQRG
     ILHRDLKLGN FFITENMELK VGDFGLAARL EPPEQRKKTI CGTPNYVAPE VLLRQGHGPE
     ADVWSLGCVM YTLLCGSPPF ETADLKETYR CIKQVHYTLP ASLSLPARQL LAAILRASPR
     DRPSIDQILR HDFFTKGYTP DRLPISSCVT VPDLTPPNPA RSLFAKVTKS LFGRKKKSKN
     HAQERDEVSG LVSGLMRTSV GHQDARPEAP AASGPAPVSL VETAPEDSSP RGTLASSGDG
     FEEGLTVATV VESALCALRN CIAFMPPAEQ NPAPLAQPEP LVWVSKWVDY SNKFGFGYQL
     SSRRVAVLFN DGTHMALSAN RKTVHYNPTS TKHFSFSVGA VPRALQPQLG ILRYFASYME
     QHLMKGGDLP SVEEVEVPAP PLLLQWVKTD QALLMLFSDG TVQVNFYGDH TKLILSGWEP
     LLVTFVARNR SACTYLASHL RQLGCSPDLR QRLRYALRLL RDRSPA
//
